Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18–25 years: A 10-year follow-up study,Asia-Pacific Journal of Clinical Oncology

当前位置： X-MOL 学术 › Asia Pac. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18–25 years: A 10-year follow-up study
Asia-Pacific Journal of Clinical Oncology ( IF 1.9 ) Pub Date : 2022-09-13 , DOI: 10.1111/ajco.13833
Fanghui Zhao ₁ , Archana Jastorff ₂ , Ying Hong ₃ , Shangying Hu ₁ , Wen Chen ₁ , Xiaoqian Xu ₁ , Yejiang Zhu ₄ , Jiahong Zhu ₅ , Xun Zhang ₁ , Wenhua Zhang ₁ , Dacheng Xu ₆ , Dali Wang ₄ , Rong Tang ₇ , Yonghong Sun ₈ , Yiping Shen ₆ , Qinjing Pan ₁ , Jian Yin ₁ , Daokuan Liu ₁ , Bin Liu ₁ , Naveen Karkada ₉ , Chunmei Jiang ₈ , Jianfeng Cui ₁ , Feng Chen ₁ , Jun Bi ₈ , Yuqing Bao ₅ , Xin Zhou ₆ , Cyrille Cartier ₉ , Yuemei Hu ₇ , Dorota Borys ₉

Affiliation

The pivotal efficacy study assessed efficacy and safety of GSK's AS04-HPV-16/18 vaccine in Chinese women aged 18–25 years up to 6 years. The present extension study, performed 4 years later, offered AS04-HPV-16/18 vaccination to placebo recipients. Vaccine safety and its long-term protective effect were assessed at Year 10.

更新日期：2022-09-13

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>